ZBTB38: A Potential Therapeutic Agent for Disrupted Cell Signaling and Cell Adhesion

Target Name: ZBTB38

NCBI ID: G253461

ZBTB38

ZBTB38: A Potential Therapeutic Agent for Disrupted Cell Signaling and Cell Adhesion

ZBTB38 (FLJ22332) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the Zinc Finger Transmembrane Protein (ZFTP) family, which is known for their role in cell signaling and inflammation. ZBTB38 has been shown to play a role in several physiological processes in the body, including the regulation of ion channels, cell adhesion, and inflammation.

One of the key functions of ZBTB38 is its role in modulating the activity of ion channels, which are responsible for the movement of charged particles (such as ions) through the cell membrane. In many tissues, these channels play a crucial role in maintaining the proper functioning of cells, and alterations in their activity can lead to a range of physiological disorders, including epilepsy, arrhythmias, and neurodegenerative diseases.

ZBTB38 has been shown to regulate the activity of several different ion channels, including the voltage-gated sodium channel (VGSA), the calcium-activated chloride channel (CaCl2), and the potassium channels. For example, studies have shown that ZBTB38 can inhibit the activity of the VGSA and CaCl2 channels, which are involved in neurotransmitter signaling and muscle contractions, respectively. This suggests that ZBTB38 may have potential as a therapeutic agent for a range of neuropsychiatric and neurological disorders.

In addition to its role in modulating ion channels, ZBTB38 has also been shown to play a key role in the regulation of cell adhesion. Adhesion is the process by which cells stick together to form tissues and organs, and it is a critical factor in the development and maintenance of tissues and organs. Alterations in cell adhesion can lead to a range of diseases, including cancer, neurodegenerative diseases, and developmental disorders.

ZBTB38 has been shown to regulate the activity of several different adhesion molecules, including cadherins and integrins. For example, studies have shown that ZBTB38 can physically interact with the cadherin protein, which is involved in cell-cell adhesion. This interaction suggests that ZBTB38 may have potential as a therapeutic agent for diseases associated with disrupted cell adhesion, such as cancer.

Finally, ZBTB38 has also been shown to play a role in the regulation of inflammation. Chronic inflammation can contribute to a range of diseases, including heart disease, neurodegenerative diseases, and autoimmune disorders. ZBTB38 has also been shown to regulate the activity of several different signaling pathways involved in inflammation, including the TGF-β pathway and the NF-kappa-B pathway.

In conclusion, ZBTB38 is a protein that is involved in a range of physiological processes in the body. Its role in modulating ion channels, cell adhesion, and inflammation makes it a potential therapeutic agent for a range of diseases. Further research is needed to fully understand the mechanisms of ZBTB38's action and its potential as a therapeutic agent.

Protein Name: Zinc Finger And BTB Domain Containing 38

Functions: Transcriptional regulator with bimodal DNA-binding specificity. Binds with a higher affinity to methylated CpG dinucleotides in the consensus sequence 5'-CGCG-3' but can also bind to E-box elements (5'-CACGTG-3'). Can also bind specifically to a single methyl-CpG pair. Represses transcription in a methyl-CpG-dependent manner (PubMed:16354688). Plays an important role in regulating DNA replication and common fragile sites (CFS) stability in a RBBP6- and MCM10-dependent manner; represses expression of MCM10 which plays an important role in DNA-replication (PubMed:24726359). Acts as a transcriptional activator. May be involved in the differentiation and/or survival of late postmitotic neurons (By similarity)

The "ZBTB38 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZBTB38 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets